Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Top 10 HIV Clinical Developments of 2016

In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

Published
02 December 2016
From
The Body Pro
China to approve 1st long-acting injection to treat HIV/AIDS

China's national drug authority on Wednesday examined clinical research results on a domestically produced anti-HIV drug in its final phase prior to officially approving the drug. Once approved, the new-generation drug, named Albuvirtide for Injection, is expected to be the world's first long-acting injection for HIV treatment.

Published
25 November 2016
From
Global Times
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine

Published
21 November 2016
From
ViiV press release
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of subjects who were given an experimental

Published
11 November 2016
By
Gus Cairns
‘Hard’ Brexit would delay access to new drugs, warns report

UK patients could see delays in access to new medicines if Brexit means leaving the single market, warns a new report published by think tank Public Policy Projects backed by health consultancy giant QuintilesIMS.

Published
09 November 2016
From
Pharma Times
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV

Ibalizumab, an experimental monoclonal antibody with a unique mechanism of action, demonstrated good safety and promising efficacy in a small phase 3 study of people with extensive

Published
04 November 2016
By
Liz Highleyman
Four days on, three days off HIV treatment controls viral load in French pilot study

An experimental `four days on, three days off` antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented

Published
03 November 2016
By
Keith Alcorn
GSK discontinues development of maturation inhibitor BMS-986173

This is disappointing news as maturation inhibitors would expect to be active about HIV that is multi-drug resistant to HIV medicines from other classes.

Published
31 October 2016
From
HIV i-Base
Darunavir/ritonavir & lamivudine matches triple-drug therapy

Simplifying antiretroviral therapy to a two-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a three-drug regimen in

Published
31 October 2016
By
Keith Alcorn
New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy

A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two

Published
28 October 2016
By
Keith Alcorn
← First12345...93Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.